healthcare · stock-sale · committee-conflict
Rep. Thomas Kean Jr. Trims Johnson & Johnson in Multi-Asset Sell-Off
The House Health subcommittee member sold JNJ stock as part of a broader, same-day portfolio rebalancing.
2026-07-20 — Thomas H. Kean Jr · JNJ
Key facts
- Rep. Thomas H. Kean Jr. sold between $1,001 and $15,000 of JNJ stock on June 2, 2026.
- Kean serves on the House Committee on Energy and Commerce's Subcommittee on Health, which oversees the pharmaceutical industry.
- The sale was part of a larger same-day rebalancing involving sales of MSFT, GOOGL, SYK, and MKL.
- JNJ shares have risen 12.85% since the sale, limiting the trade's immediate financial advantage.
Rep. Thomas H. Kean Jr. (R-N.J.) disclosed a sale of Johnson & Johnson (JNJ) stock valued between $1,001 and $15,000, executed on June 2, 2026.
Kean sits on the House Committee on Energy and Commerce and its Subcommittee on Health, which holds direct legislative and oversight jurisdiction over the pharmaceutical sector, including drug pricing and public health policies that govern Johnson & Johnson. However, the transaction appears to be part of a broader, same-day portfolio adjustment rather than a targeted exit from the healthcare giant. On the same day, Kean executed sales of several other major holdings, including Microsoft (MSFT), Alphabet (GOOGL), Stryker (SYK), and Markel (MKL), alongside a single purchase of Gates Industrial (GIL).
Our analysis scored the trade's signal strength at a modest 28 out of 100, largely because it aligns with Kean's established trading history. The representative has been systematically trimming his JNJ position, recording five periodic sales since July 2025 without executing a single purchase. The timing of the trade also meant missing out on a subsequent rally; since the June 2 transaction, JNJ shares have risen 12.85%, climbing from $222.89 to $251.53.
While Kean was selling, other market participants were moving in different directions. On the same day as Kean's transaction, Rep. Ro Khanna (D-Calif.) purchased JNJ stock. On the corporate side, Johnson & Johnson filed financial updates earlier in the spring [1, 2], and Executive Vice President Kathryn E. Wengel subsequently executed an open-market sale of 10,000 shares on June 11, 2026, following option exercises.
Members of Congress are required by the STOCK Act to disclose trades within 45 days, and disclosed amounts are reported in ranges. Kean filed his disclosure on July 15, 2026, 43 days after the transaction.
For Kean, the steady unwinding of his pharmaceutical holdings continues—even if it means leaving some of JNJ's recent gains on the table.
Sources
- Johnson & Johnson Form 8-K (April 14, 2026) — SEC EDGAR
- Johnson & Johnson Form 8-K (April 28, 2026) — SEC EDGAR
- Kathryn E. Wengel Form 4 Filing — SEC EDGAR